Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.20

-5.5%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (4456)	8/17/2001 3:57:29 AM
From: nigel bates	Read Replies (2) of 52153

Interesting genomeweb article on the various Bayer deals, including the little discussed Lion one - genomeweb.com (Clulow, the UBS Warburg analyst, separately told GenomeWeb that Lion “is very close” to signing “several deals” similar to the one it struck with Bayer. He added that while Bayer “accounts for a good chunk” of Lion’s revenues today, “that customer concentration will diminish six months from now.” He expects Lion to announce the new deals in the next quarter.).... ...Besides, added von Bohlen, “there is no change-of-control clause in our contract with Bayer. That is why we sleep well at night.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next